T he PLATO trial was a phase 3, randomized, double-blind, parallel-group, multinational, clinical study comparing the efficacy of ticagrelor (formerly known as AZD6140, marketed as Brilinta) versus standard care treatment with clopidogrel. Patients (n=18 624) with moderate-to high-risk acute coronary syndrome undergoing coronary intervention or medically managed were randomized to ticagrelor 180 mg loading dose followed by 90 mg twice daily thereafter, or clopidogrel 300 to 600 mg loading dose followed by 75 mg once daily for 6 to 12 months. 1 The primary end point was the time of the first event of death from vascular causes, myocardial infarction or stroke, and occurred in 11.7% of patients treated with clopidogrel, versus 9.8% of patients randomized to ticagrelor, representing a highly significant benefit (hazard ratio [HR]=0.84; CI=0.77-0.92; P<0.001) for ticagrelor.
1 Importantly, the benefit of ticagrelor was driven equally by the reduction of vascular death (P<0.001), and myocardial infarction (P<0.005) with 89 events favoring ticagrelor each, but not stroke (P=0.22) with 19 less events in the clopidogrel arm. 1 (Table 2) . 2 Patients who had a history of cerebrovascular disease on ticagrelor had a >5-fold increase in the risk of a stroke or TIA compared with all patients on ticagrelor (8.1% versus 1.59%; relative risk=5.1). 2 Clopidogrel-treated patients with a history of cerebrovascular disease also had an increase in the risk of a stroke or TIA compared with all patients treated with clopidogrel (4.0% versus 1.49%; relative risk=2.5), albeit half the increased risk that was associated with ticagrelor. 2 Moreover, compared with clopidogrel, patients on ticagrelor had a 2-fold increase in major or life-threatening intracranial hemorrhage (n=27 These complete response review data are in direct contrast to a recent editorial that indicated an equal amount of intracranial hemorrhagic events among patients with a history of stroke or TIA on ticagrelor and clopidogrel (4 versus 4, respectively). 3 Moreover, authors state that among patients with a history of stroke or TIA, the primary composite outcome was not significantly reduced at 1 year with ticagrelor versus clopidogrel (HR=0.87; 95% CI= 0.66-1.13; P=0.84), yet there was a significant reduction in mortality (HR=0.62; 95% CI=0.42-0.91). Additionally, overall PLATO defined bleeding rates were similar between ticagrelor and clopidogrel (14.6% versus 14.9%; HR=0.99; 95% CI=0.71-1.37, respectively). Thus, the Editorial concludes that acute coronary syndrome patients with a prior history of ischemic stroke or TIA had a favorable net benefit because of ticagrelor's reduction on mortality. 3 However, an editorial by Verheugt indicates that an interaction between ticagrelor and intracranial hemorrhage in patients with previous stroke cannot be ruled out. 4 The low number of patients with previous stroke having an intracranial hemorrhage in the PLATO trial prevents the exclusion of an interaction, and because of this, we do not have enough data to confirm that ticagrelor is safe in acute coronary syndrome patients with a previous stroke or TIA ( Table 2) . 4 Importantly, in the ongoing Prevention of Cardiovascular Events (ie, death from heart or vascular disease, heart attack, or stroke) in Patients With Prior Heart Attack Using Ticagrelor Compared to Placebo on a Background of Aspirin (PEGASUS) trial, testing ticagrelor in patients with stable coronary disease, patients with a background of ischemic stroke are specifically excluded. Moreover, the PLATO mortality data has recently been questioned, with results varying by geographical location. In the United States, the primary end point was increased with ticagrelor compared with clopidogrel (HR=1.27; 95% CI=0.92-1.75). Somewhat concerning was that 46% of the entire ticagrelor benefit in PLATO was driven by 2 countries (Poland and Hungary). 5 These 2 countries were monitored by the PLATO sponsor, in contrast to the United States, where a third party independent contract research organization was used. Additionally, clopidogrel beats ticagrelor in Russia and Georgia, which were also regulated by an independent contract research organization, Worldwide Clinical Trials (King of Prussia, PA). 5 However, the regional differences, which may well be the result of conduct and monitoring discrepancies, were not analyzed by the Food and Drug Administration complete response review documents. Indeed, regional differences in blood pressure control, concomitant medications, length of hospital stay, ratio of other types of bleeding events to intracranial bleeds, or just heterogeneity of patient data might benefit future trial designs. Finally, the concept of net clinical benefit has been somewhat challenged in the recently published The Third International Stroke Trial (IST-3). 6 The advantages of calculating net benefit may be soon revised because of different weights of outcome measures and large heterogeneity of the modern trial cohorts.
In summary, we presently cannot be certain regarding the reported ticagrelor-mortality benefit. 5 However, compared with clopidogrel-treated patients with a history of cerebrovascular disease, patients on ticagrelor are at a 2-fold increased risk for a recurrent stroke or TIA, a 2-fold increased risk for an intracranial hemorrhage complication, and a 10-fold increased risk for a fatal intracranial hemorrhage. 2 Thus, in patients with a history of cerebrovascular disease, the net clinical benefit with ticagrelor compared with clopidogrel is heavily challenged. In fact, compared with clopidogrel, ticagrelor seems to carry a net clinical harm, especially because the primary end point was not reduced in these individuals. 
